GMED
Globus Medical, Inc.
Is GMED Halal?
Spine, orthopedic and neurotechnology medical-device manufacturing — generally permissible activity whose known current asset-based ratios pass, with activity classification incomplete.
What You Should Know
Globus Medical's March 31, 2026 Form 10-Q reports assets of $5,439.555 million, finance-lease debt of $0.718 million, cash of $560.950 million, marketable debt securities of $238.338 million, receivables of $686.433 million and quarterly net sales of $759.854 million. Debt/assets is 0.01%, liquidity/assets is 14.69%, receivables plus cash/assets is 22.93% and reported net interest income/expense is 0.72% of revenue. Known asset-based ratios pass, but no universal prohibited-revenue numerator is disclosed.
⚠️ Concerns
- •Known asset-based ratios pass, but no universal prohibited-revenue numerator is disclosed
- •Large corporate and government debt-security portfolio
- •Spine, orthopedic and neurotechnology product and end-market mix
- •Acquisition integration, regulatory and product-liability exposure
- •Reported net interest income/expense is 0.72% of quarterly revenue; no fixed purification percentage asserted
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
0.718 / 5,439.555
799.288 / 5,439.555
1,247.383 / 5,439.555
5.434 / 759.854
- Financial
- Pass
- Overall
- Incomplete
Debt/assets is 0.01%, liquidity/assets is 14.69%, receivables-plus-cash/assets is 22.93% and reported net interest income/expense is 0.72%; activity remains qualitative.
- Financial
- Pass
- Overall
- Incomplete
Known debt, liquidity and receivables-plus-cash ratios are below the examined MSCI limits; this is not an index-membership claim and activity remains incomplete.
- Financial
- Pass
- Overall
- Incomplete
Debt/assets and identifiable liquidity/assets are below the examined Malaysia limits; this is a calculation against SAC ratios, not an official classification.
- Financial
- Not calculated
- Overall
- Incomplete
A licensed historical market-cap series is not stored; filing-based asset ratios remain documented.
Business-activity disclosure
Globus Medical develops and manufactures musculoskeletal and neurotechnology products, including spine, orthopedic and neuromodulation devices. The core medical-device activity is generally permissible, but the filing does not provide a universal prohibited-revenue numerator for product or customer end uses.
Limitation: No universal prohibited-activity revenue numerator or scholar-specific purification percentage is disclosed; product and clinical-use allocation remains qualitative.
Purification
The filing reports net interest income/expense of $5.434 million; ZakatInvest does not prescribe a fixed scholar-approved purification percentage.
Inputs, assumptions and primary sources
- Amounts are USD millions from Globus Medical's March 31, 2026 Form 10-Q.
- Interest-bearing debt uses the $0.718 million finance-lease liability; no conventional borrowings are reported and operating leases are excluded.
- Cash is $560.950 million and marketable securities are $238.338 million, comprising short- and long-term corporate and government debt securities; net accounts receivable are $686.433 million.
- First-quarter net sales are $759.854 million and reported net interest income/expense is $5.434 million (0.72% of revenue).
- Medical-device and neurotechnology activity is retained as qualitative analysis; no universal prohibited-revenue numerator is disclosed.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →